Drugs / VCL-IM01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00223899 | Jul 2005 → Jun 2008 | metastatic melanoma | Vical | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VCL-IM01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00223899 ↗ |
| Modality | Other / unclassified | “IL-2-encoding plasmid formulated in phosphate-buffered saline” NCT00223899 ↗ |
| Route | Other | “intratumorally injected” NCT00223899 ↗ |
| Target | IL2 | “IL-2-encoding plasmid” NCT00223899 ↗ |